HIV

3 Blockbuster Drug Launches to Watch This Year
3 Blockbuster Drug Launches to Watch This Year
Motley Fool
drug launches
GSK
Cabenuva
HIV
ViiV
Gilead Sciences
Trodelvy
Eli Lilly
Retevmo
cancer
Flag link:
FDA approves first monthly injectable to treat HIV infection
FDA approves first monthly injectable to treat HIV infection
Stat
ViiV
FDA
Cabenuva
HIV
Flag link:
Fierce Pharma's top 2020 marketing stories pack pandemic punch to digital, reputation and drug launches
Fierce Pharma's top 2020 marketing stories pack pandemic punch to digital, reputation and drug launches
Fierce Pharma
pharma marketing
drug pricing
COVID-19
pandemic
remdesivir
Gilead Sciences
HIV
PrEP
Pfizer
Flag link:
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir
Pharmaforum
Gilead Sciences
lenacapavir
HIV
Flag link:
GSK and ViiV score breakthrough therapy designation in HIV prevention, as Truvada showdown draws nearer
GSK and ViiV score breakthrough therapy designation in HIV prevention, as Truvada showdown draws nearer
Endpoints
GSK
ViiV
FDA
cabotegravir
HIV
PrEP
Flag link:
GSK’s ViiV Healthcare caps virtual HIV summit with a Facebook Live cabaret
GSK’s ViiV Healthcare caps virtual HIV summit with a Facebook Live cabaret
Fierce Pharma
GSK
ViiV
HIV
Facebook
drug marketing
Flag link:
GSK reports its long-acting HIV PrEP tops Gilead's Truvada — again
GSK reports its long-acting HIV PrEP tops Gilead's Truvada — again
Endpoints
GSK
ViiV
cabotegravir
HIV
PrEP
FDA
Flag link:
Gilead announces new data on Biktarvy for the treatment of HIV in Black Americans
Gilead announces new data on Biktarvy for the treatment of HIV in Black Americans
Pharmaceutical Business Review
Gilead Sciences
Biktarvy
HIV
Flag link:
GSK's ViiV, armed with long-term Dovato data, eyes 'tipping point' for 2-drug HIV regimen
GSK's ViiV, armed with long-term Dovato data, eyes 'tipping point' for 2-drug HIV regimen
Fierce Pharma
GSK
ViiV
Dovato
HIV
Flag link:
Gilead got a boost from a newly approved PrEP drug. Now, a major insurer is dropping coverage
Gilead got a boost from a newly approved PrEP drug. Now, a major insurer is dropping coverage
MedCity News
Gilead Sciences
UnitedHealthcare
PrEP
HIV
Descovy
Truvada
Flag link:
Moderna to open COVID-19 vaccine trials to people with HIV
Moderna to open COVID-19 vaccine trials to people with HIV
Beckers Hospital Review
Moderna Therapeutics
clinical trials
mRNA-1273
vaccines
HIV
Flag link:
ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato
ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato
Pharmaceutical Business Review
ViiV Healthcare
FDA
HIV
Dovato
HIV-1
Flag link:
GSK’s latest pipeline review includes a slate of COPD programs headed to the scrap heap
GSK’s latest pipeline review includes a slate of COPD programs headed to the scrap heap
Endpoints
GSK
R&D
COPD
HIV
cancer
Flag link:
CytoDyn shares slammed as BLA filing for leronlimab in HIV hits a wall
CytoDyn shares slammed as BLA filing for leronlimab in HIV hits a wall
Endpoints
CytoDyn
leronlimab
HIV
FDA
Flag link:
After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure
After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure
Endpoints
Merck
Dewpoint Therapeutics
HIV
R&D
Flag link:
GSK sets the stage for a toe-to-toe market showdown with Gilead's HIV champion Truvada
GSK sets the stage for a toe-to-toe market showdown with Gilead's HIV champion Truvada
Endpoints
GSK
Gilead Sciences
ViiV Healthcare
HIV
cabotegravir
Truvada
Flag link:
GSK snags first-in-class FDA nod for Rukobia to treat HIV patients who have few options
GSK snags first-in-class FDA nod for Rukobia to treat HIV patients who have few options
Fierce Pharma
GSK
ViiV Healthcare
Rukobia
fostemsavir
HIV
FDA
Flag link:
ViiV Healthcare gets FDA nod for HIV drug Rukobia to treat adult patients
ViiV Healthcare gets FDA nod for HIV drug Rukobia to treat adult patients
Pharmaceutical Business Review
ViiV Healthcare
FDA
Rukobia
HIV
Flag link:
New Data Shows Promise Involving Lenacapavir for the Treatment of HIV
New Data Shows Promise Involving Lenacapavir for the Treatment of HIV
BioSpace
Gilead Sciences
lenacapavir
HIV
Flag link:
Experimental HIV drug seems effective at a twice-a-year dose, study finds
Experimental HIV drug seems effective at a twice-a-year dose, study finds
Stat
HIV
Gilead Sciences
lenacapavir
clinical trials
Flag link:

Pages